Year: 2025

NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW CALGARY, Alberta, Dec. 17, 2025 (GLOBE NEWSWIRE) —  Unless otherwise stated, all numbers in this press release are presented in Canadian dollars. Alaris Equity Partners Income Trust (“Alaris” or the “Trust“) (TSX: AD.UN) is pleased to announce that it has completed its previously announced offering of convertible unsecured senior debentures (“Debentures“) with a syndicate of underwriters (the “Underwriters”) led by National Bank Capital Markets and CIBC Capital Markets and including Desjardins Capital Markets, Acumen Capital Finance Partners Limited, Raymond James Ltd., RBC Capital Markets, Scotiabank and Cormark Securities Inc. A total of $115 million...

VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (“GoldHaven” or the “Company”) is pleased to provide a comprehensive update on its inaugural diamond drilling program at the Copeçal Project, further to its previous press releases announcing the commencement of drilling, the intersection of sulphide mineralisation in Hole COPE-PDH-004, and the subsequent drilling of a follow-up Hole COPE-PDH-009. HighlightsInaugural diamond drilling program successfully completed at the Copeçal Project, marking the first-ever diamond drilling campaign on the property, with nine holes totaling 1,085.7 metres completed. Sulphide mineralisation intersected at the Eastern Gold-in-Soil Anomaly, including chalcopyrite–pyrite over ~30 metres in Hole COPE-PDH-004 and bornite–chalcopyrite–pyrite over ~5 metres in...

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that it has initiated a first-in-human Phase 1 clinical study of ACCG-2671, the company’s lead oral small molecule amylin receptor agonist for the treatment of obesity. ACCG-2671 was designed via the company’s next generation structure-based drug discovery platform to harness the established metabolic benefits of amylin biology in an oral, once-daily small molecule, with the potential to improve scalability, combinability, and patient access. “We believe amylin-based therapies are poised to become an important next-generation component of the treatment landscape for obesity and...

Geneva, Switzerland, Dec. 17, 2025 (GLOBE NEWSWIRE) — SEALSQ Owns 28.3% Stake in WECAN Via Strategic Investments Focused on Quantum Technology Integration SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that WeCanGroup SA (“WECAN”), a blockchain-based solutions entity in which SEALSQ owns a 28.3% minority stake, was awarded a grant from Hedera. The receipt of the grant represents a new milestone for WECAN following the completion of a strategic investment made by SEALSQ earlier this year focused on the integration of its semiconductor, PKI, and post-quantum technologies into WECAN’s compliance and secure data-exchange platforms. The grant awarded by Hedera...

New York, NY and Sydney, Australia, Dec. 17, 2025 (GLOBE NEWSWIRE) — Integrated Wellness Acquisition Corp (OTC: WELNF) (“IWAC”), a publicly traded special purpose acquisition company, today announced that its shareholders have voted to approve the previously announced business combination with Btab Ecommerce Group, Inc., (OTC: BBTT) (“Btab”), a global e-commerce and technology company. The vote occurred at IWAC’s Extraordinary General Meeting of Shareholders held on December 8, 2025, during which all shareholder proposals required to consummate the merger were approved. The business combination is expected to close following the satisfaction or waiver of customary closing conditions outlined in the proxy statement/prospectus filed with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to obtaining applicable...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) — Rio2 Limited (“Rio2” or the “Company”) (TSX: RIO; OTCQX: RIOFF; BVL: RIO) is pleased to announce the closing of its previously announced brokered private placement (the “Private Placement”). A total of 6,306,300 common shares of the Company (the “Shares”) were sold to investors resident in Peru and Chile at a price per Share of C$2.22 (approximately US$1.585) for aggregate gross proceeds to the Company of C$14 million (approximately US$10 million) KALLPA Securities Sociedad Agente de Bolsa S.A. acted as the Company’s agent for the Private Placement. ‎ The Company plans to use the net proceeds from the Private Placement for working capital and general corporate purposes....

Gross proceeds before costs equal ~A$139M (~C$127.3M) Not for distribution to United States wire services or dissemination in the U.S. TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) — FireFly Metals Ltd (ASX: FFM, TSX: FFM) (FireFly or the Company) is pleased to announce that it has completed the equity raising announced on 2 and 4 December 2025 and comprising the following (Equity Raising):A$85.0 million (~C$77.8 million)1 institutional placement at a price of A$1.70 per share (Institutional Placement), which completed on 12 December 2025; C$34.5 million (~A$37.7 million)1 Canadian bought deal offering at a price of C$1.56 per share (Canadian Offering), which completed on 17 December 2025; and ~A$16.4 million (C$15.0 million)2 charity flow-through placement to Canadian investors priced at approximately A$2.09 per share (Charity Flow-Through...

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 Trial Builds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid TherapiesBOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease (AD). This milestone follows the Company’s December 12, 2025 announcement that enrolment had begun and the first patient was expected to be dosed imminently....